**Description**

**A COMPOSITION COMPRISING SYNTHETIC COMPONENTS THAT EXHIBIT ANTI-INFLAMMATORY ACTION WITH THE CHARACTERISTIC OF SUPPRESSING NF-KAPPA B**

**Technical Field**

The invention relates to a composition formed for suppressing nf-kappa b.

**State of the Art**

NF-kappa B (NF-κB, Nuclear Factor kappa B) is a transcription factor available in all the cell types. It is present in cytoplasm in inactive state. When activated, it is translocated to the nucleus. It has 5 types: NF-κB1, NF-κB2, RelA (p65), RelB and c-Rel. NF-kappa B is thought to have an effect on some autoimmune diseases (e.g. ulcerative colitis, Crohn).

According to the state of the art, the invention no. EP1499729B1 with classification "A61K 31/711" entitled "Derivatives of NF-kappa-b inducing enzyme, their preparation and use" relates to the use of NIK and related molecules for the modulation of signal activities controlled by cytokines, and some new such molecules.

As a result, the presence of the need for a composition for suppressing nf-kappa b and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art.

**Object of the Invention**

In order to eliminate the disadvantages of the state of the art, an object of the invention is to enable the suppression of nf-kappa-B.

Another object of the invention is to enable the suppression of cox-2.

Another object of the invention is to enable the suppression of FMO3.

Another object of the invention is to enable the suppression of PGE2.

Another object of the invention is to provide the triggering of the increase in the level of endogenous cAMP.

In order to achieve the aforesaid advantages, the invention is a composition for suppressing nf-kappa b, said composition being obtained by the components selected from the group comprising 4-​dimethyl-​N2-​(2-diphenylcoumaroyl)-​1,​2-​symplocomoside-taurinate, 2,2-dimethyl-​N3​(3-triphenylpropyl)-​2​2-​difluoro-symplocomoside-arginate that are used individually or in combinations.

The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and therefore, the evaluation must be made taking this detailed description into consideration.

**Detailed Description of the Invention**

The invention is a composition formed for suppressing nf-kappa b. Said invention enables the suppression of nf-kappa B, the suppression of cox-2, the suppression of FMO3, the suppression of PGE2 and provides the triggering of the increase in the level of endogenous cAMP.

The composition according to the invention contains 4-​dimethyl-​N2-​(2-diphenylcoumaroyl)-​1,​2-​symplocomoside-taurinate, 2,2-dimethyl-​N3​(3-triphenylpropyl)-​2​2-​difluoro-symplocomoside-arginate.

Said composition is obtained by a mixture of the aforesaid components according to the following ratios by weight:

1-99% 4-​dimethyl-​N2-​(2-di​phenylcoumaroyl)-​1,​2-​symplocomoside-taurinate,

99-1% 2,2-dimethyl-​N3​(3-triphenylpropyl)-​2​2-​difluoro-symplocomoside-arginate.

The composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations.

Said invention also encompasses the use of said composition for suppressing nf-kappa b and the manufacture thereof for this purpose.

**CLAIMS**

1. A composition for suppressing nf-kappa b, said composition being obtained by the components selected from the group comprising 4-​dimethyl-​N2-​(2-diphenylcoumaroyl)-​1,​2-​symplocomoside-taurinate, 2,2-dimethyl-​N3​(3-triphenylpropyl)-​2​2-​difluoro-symplocomoside-arginate that are used individually or in combinations.
2. A composition according to Claim 1 characterized in that it comprises 1-99% by weight 4-​dimethyl-​N2-​(2-di​phenylcoumaroyl)-​1,​2-​symplocomoside-taurinate.
3. A composition according to Claim 1 characterized in that it comprises 99-1% by weight 2,2-dimethyl-​N3​(3-triphenylpropyl)-​2​2-​difluoro-symplocomoside-arginate.
4. Use of the components according to Claims 1 to 3 obtained individually or in combinations selected from the group consisting of 4-​dimethyl-​N2-​(2-diphenylcoumaroyl)-​1,​2-​symplocomoside-taurinate, 2,2-dimethyl-​N3​(3-triphenylpropyl)-​2​2-​difluoro-symplocomoside-arginate for the manufacture of a composition for suppressing nf-kappa b.

**ABSTRACT**

**A COMPOSITION COMPRISING SYNTHETIC COMPONENTS THAT EXHIBIT ANTI-INFLAMMATORY ACTION WITH THE CHARACTERISTIC OF SUPPRESSING NF-KAPPA B**

The invention relates to a composition formed for suppressing nf-kappa b.

No figure.